Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ferrosoferric oxide
Drug ID BADD_D00886
Description Ferumoxytol is an intravenously administered iron preparation indicated in the EU and the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD) [A32478]. It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively high dose by rapid intravenous injection [L2181].
Indications and Usage Investigated for use/treatment in anemia, kidney disease, and cardiovascular disorders.
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB06215
KEGG ID Not Available
MeSH ID D052203
PubChem ID 14789
TTD Drug ID D06CTM
NDC Product Code 59338-775; 0781-3154
Synonyms Ferrosoferric Oxide | Oxide, Ferrosoferric | Ferriferrous Oxide | Oxide, Ferriferrous | Magnetite | Feraheme | Ferumoxytol
Chemical Information
Molecular Formula Fe3H2O4
CAS Registry Number 1317-61-9
SMILES O[Fe]=O.O[Fe]=O.[Fe]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyspnoea22.02.01.004; 02.01.03.002--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.001--
Eye disorder06.08.03.001--Not Available
Faeces discoloured07.01.03.002--Not Available
Fatigue08.01.01.002--
Feeling hot08.01.09.009--Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.002--
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Glossodynia07.14.02.001--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Haemoglobin13.01.05.018--Not Available
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypotension24.06.03.002--
Hypoxia22.02.02.003--
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.042--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.013--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Lacrimation increased06.08.02.004--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages